Search clinical trials for: imatinib Mesylate

Total 1353 results

Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Leukemia

United States
University of California, San Francisco
Novartis

Completed

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Unspecified Adult Solid Tumor

United States
Inova Health Care Services
Novartis Pharmaceuticals

Completed

New Individualized Therapy Trial for Metastatic Colorectal Cancer (NITMEC)

Colorectal Cancer | Colorectal Neoplasm

United States
University Hospital, Bordeaux

Completed

Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM-FU)

Chronic Myeloid Leukemia

France
Medical University of South Carolina
Columbia University

Completed

LAM Pilot Study With Imatinib Mesylate (LAMP-1)

Lymphangioleiomyomatosis

United States
Alexandria University
Science, Technology & Innovation Funding Authority (STIFA), Egypt

Unknown

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

COVID-19
University of Malaya

Unknown

Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy

Postoperative Pain | Renal Transplantation | Morphine Adverse Reaction

Malaysia
David Miklos
Novartis

Completed

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

Graft vs Host Disease

United States
Poitiers University Hospital
Novartis; Roche Pharma AG; Ministry of Health, France

Completed

STI571 ProspectIve RandomIzed Trial: SPIRIT (SPIRIT)

Chronic Myeloid Leukemia

France
National Cancer Institute (NCI)

Completed

Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease

Sclerotic Graft Versus Host Disease | Imatinib Mesylate

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; University of Pittsburgh

Completed

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Advanced Gastrointestinal Stromal Tumor (GIST)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

Leukemia

United States
University of California, San Francisco
Juvenile Diabetes Research Foundation

Completed

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDM

United States, Australia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Disease | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Adult B Acute Lymphoblastic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | Progesterone Receptor Positive | Postmenopausal | KIT Positive | PDGFR Positive

United States
Astex Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Gastrointestinal Stromal Tumor (GIST)

United States
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Yonsei University

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Fibromatosis

Korea, Republic of
Asan Medical Center

Completed

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Gastrointestinal Stromal Tumors

Korea, Republic of
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
YD Global Life Science Co., Ltd.

Unknown

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Diabetic Macular Edema(DME)

United States, Korea, Republic of
Asan Medical Center

Completed

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

Sarcoma | Gastrointestinal Stromal Tumors

Korea, Republic of
Aligarh Muslim University

Completed

Dexamethasone vs Bicarbonate to Intracuff Lignocaine 2% in General Anaesthesia

Anesthesia | Anesthesia Intubation Complication | Anesthesia; Adverse Effect

India
AB Science

Terminated

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

United States, France, Lebanon
University of Milano Bicocca

Completed

Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV)

Chronic Myeloid Leukemia

Canada, Germany, Israel, Italy, Spain
Prof. Dr. Nikolas von Bubnoff
Novartis

Terminated

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years (DECLINE)

Chronic Myeloid Leukemia

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Adult Anaplastic Oligodendroglioma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain Neoplasm

United States
UMC Utrecht
Erasmus Medical Center; Meander Medical Center; Hubrecht Institute

Terminated

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy (ImPACCT)

Colonic Neoplasms

Netherlands
National Taiwan University Hospital
National Cheng-Kung University Hospital; Far Eastern Memorial Hospital; Tri-Service... and other collaborators

Terminated

Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT

Taiwan
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China
Peking University People's Hospital
Peking University First Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaborators

Unknown

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma (CSSG-03)

Quality of Life | Advanced Cancer | Chordoma | Effect of Drugs

China
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
University Hospital, Lille
Novartis

Completed

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (DoubleITK)

Graft Versus Host Disease

France, Belgium
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Imperial College London
Novartis Pharmaceuticals

Completed

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Chronic Myeloid Leukemia | Newly Diagnosed

United Kingdom
Boston Children's Hospital

Completed

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis (PVS)

Pulmonary Veno Occlusive Disease

United States
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Shanghai Zhongshan Hospital

Unknown

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Surgery | Gastrointestinal Stromal Tumors
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Head and Neck Cancer

United States, Canada
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia (LAL0904)

Leukemia

Italy
Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Chronic Myeloid Leukemia

France, United States, Spain, Belgium, Singapore, Poland, Canada, Japan, United Kingdom, Taiwan, Hungary, Germany, Argentina, Russian Federation, Turkey, Colombia, Italy, South Africa, Brazil, Chile, China, Hong Kong, India, Korea, Republic... and more
University of Washington
National Cancer Institute (NCI)

Withdrawn

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
Emory University

Terminated

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Leukemia | Chronic Myeloid Leukemia | Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Melanoma | Skin Neoplasms

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Myelogenous Leukemia, Chronic, Chronic Phase

United States
Nurex S.r.l.
Purdue University; Università degli Studi di Sassari; Vinmec Healthcare System

Unknown

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites (Artesynib)

Plasmodium Falciparum Malaria (Drug Resistant)

Vietnam

Search clinical trials for: imatinib Mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations